C86.61
Primary cutaneous CD30-positive T-cell proliferations, in remission
Clinical Classification Guidelines
Medical Intelligence & Overview
Primary cutaneous CD30-positive T-cell proliferations are a group of skin conditions characterized by abnormal growths of T-cells that express the CD30 protein. When these proliferations are in remission, it indicates that the disease activity has subsided following treatment. The ICD-10 code C86.61 specifically refers to patients with this type of condition who are currently in a phase of remission, meaning they have no active symptoms or detectable disease at this time.
Causes & Symptoms
Clinical Causes: Certain types of lymphoproliferative disorders characterized by the abnormal growth of T-cells. Genetic mutations leading to uncontrolled T-cell proliferation. Immune system factors that may influence abnormal T-cell activity. Potential triggers include infections or immune responses, though specific causes are often unknown.
Key Symptoms: Skin lesions such as patches, plaques, or nodules that can appear on various parts of the body. Itching or discomfort associated with skin lesions. Possible redness or swelling of the affected areas. In some cases, lesions may ulcerate or become infected.
Diagnostic & Treatment
Diagnosis Path: Diagnosis of primary cutaneous CD30-positive T-cell proliferations involves a combination of clinical evaluation and laboratory tests. A dermatologist will examine the skin and may perform a skin biopsy to analyze tissue samples under a microscope. Immunohistochemical staining is used to identify CD30 protein expression on T-cells. Additional tests, such as imaging or blood work, may be employed to rule out systemic involvement and confirm the skin-limited nature of the disease. The remission status may be determined through follow-up assessments indicating absence of active lesions or disease markers.
Treatment Protocols: Topical therapies such as corticosteroids or targeted medications to reduce inflammation and control skin lesions. Phototherapy (light therapy) to eliminate proliferating T-cells in the skin. Systemic treatments including chemotherapy or immunotherapy, in cases of more extensive disease or recurrence. Regular follow-up appointments to monitor for disease activity or recurrence, especially during remission.
Clinical Advice & FAQs
Billing Guidance
Is C86.61 a billable ICD-10 code?
Yes, C86.61 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C86.61?
Clinical documentation must specify the nature of Primary cutaneous CD30-positive T-cell proliferations, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference